Psychedelic-Derived Deal Benchmarks in Neurology

Median Upfront

$378M

Range: $188M - $571M

Total Deal Value

$3.3B

Range: $2.0B - $4.7B

Royalty Rate

12.7% - 20.3%

Tiered up to 24.3%

Dev Milestones

$978M

Range: $600M - $1.4B

Model Your Deal

Market Analysis

Psychedelic-Derived therapies in neurology have seen significant M&A and licensing activity in recent years. Based on analysis of 1,400+ verified transactions, the median upfront payment for a Phase 2 psychedelic-derived asset in neurology is $378M, with total deal values reaching $3.3B. Development milestones average $978M, while regulatory milestones contribute $1.1B.

The neurology psychedelic-derived landscape is characterized by moderate competitive intensity with significant unmet need in neurodegenerative indications. Disease-modifying therapies and novel CNS delivery platforms are attracting increasing licensee interest following breakthroughs in amyloid-targeted approaches. The recommended deal structure allocates approximately 11% to upfront payments and 89% to milestones, reflecting the risk-reward profile at the Phase 2 stage.

Royalty rates for psychedelic-derived neurology deals range from 12.7% to 20.3% at the base tier, with tiered escalation reaching 16.7%-24.3% on blockbuster sales. Commercial milestones averaging $919M further reward successful market penetration.

PRO

Full Benchmark Analysis

Complete deal term ranges, comparable transactions, and negotiation insights.

Start 7-Day Free Trial

$299/mo after trial · Cancel anytime

Customize these benchmarks for your asset

Adjust phase, modality, competitive position, and 10+ other parameters.

Open Calculator

Frequently Asked Questions

What is the typical upfront for a psychedelic-derived neurology licensing deal?

Based on our analysis, Phase 2 psychedelic-derived licensing deals in neurology average $378M in upfront payments, with a range of $188M to $571M depending on data quality, competitive positioning, and territorial scope.

What is the total deal value for psychedelic-derived neurology transactions?

The median total deal value for Phase 2 psychedelic-derived assets in neurology is $3.3B, ranging from $2.0B to $4.7B. This includes development milestones ($978M), regulatory milestones ($1.1B), and commercial milestones ($919M).

What royalty rates are standard for psychedelic-derived deals in neurology?

Base royalty rates for psychedelic-derived neurology transactions range from 12.7% to 20.3%, with tiered escalations reaching 16.7%-24.3% on peak sales. Rates are influenced by mechanism differentiation, competitive landscape, and territorial scope.

How are milestones structured in psychedelic-derived neurology deals?

Psychedelic-Derived neurology deals allocate approximately 89% of total deal value to milestones. Development milestones ($978M) make up the largest share, followed by commercial milestones ($919M) and regulatory milestones ($1.1B).

PRO

Full Benchmark Analysis

Complete deal term ranges, comparable transactions, and negotiation insights.

Start 7-Day Free Trial

$299/mo after trial · Cancel anytime

Related Benchmarks

Small Molecule in Neurology

View

Monoclonal Antibody in Neurology

View

Ready to Calculate Your Deal Terms?

Get instant, customized benchmarks based on real market data from 1,400+ biopharma licensing deals.

Start Calculating

For Funds & Advisors

Need a decision for one asset?

The Deal Intelligence Brief turns this landscape into a decision for one asset — a signed recommendation with ask, floor and walk-away, cited comparables, buyers ranked on evidence, and a 24-month catalyst calendar. Reviewed by the Managing Partner; delivered within 24 hours of the intake call.

Configure Brief — $2,500About 30 data-backed pages · Invoiced at intake · 30-minute walkthrough